ImmuCell (NASDAQ:ICCC) Upgraded to Strong-Buy at Wall Street Zen

ImmuCell (NASDAQ:ICCC) was upgraded by equities research analysts at Wall Street Zen to a “strong-buy” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings downgraded ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, ImmuCell has an average rating of “Sell”.

ImmuCell Trading Down 1.0%

Shares of ICCC stock opened at $9.79 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.60 and a current ratio of 4.82. The stock has a fifty day simple moving average of $9.22 and a two-hundred day simple moving average of $7.37. The firm has a market capitalization of $88.60 million, a PE ratio of -163.14 and a beta of 0.55. ImmuCell has a 52-week low of $4.52 and a 52-week high of $10.75.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.05 by $0.16. The business had revenue of $10.36 million for the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a negative return on equity of 1.88% and a negative net margin of 1.82%.

Insiders Place Their Bets

In related news, CEO Boekhorst Paul Francis Oliv Te bought 8,000 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The stock was bought at an average cost of $9.49 per share, with a total value of $75,920.00. Following the completion of the purchase, the chief executive officer owned 17,785 shares of the company’s stock, valued at approximately $168,779.65. The trade was a 81.76% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 5.70% of the company’s stock.

Institutional Trading of ImmuCell

Several hedge funds have recently bought and sold shares of ICCC. Steadtrust LLC bought a new stake in ImmuCell in the 3rd quarter worth approximately $198,000. Mesirow Financial Investment Management Inc. boosted its position in shares of ImmuCell by 199.6% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after acquiring an additional 24,303 shares during the last quarter. Militia Capital Management LLC bought a new position in shares of ImmuCell during the 1st quarter valued at approximately $114,000. Geode Capital Management LLC grew its holdings in shares of ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 2,907 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of ImmuCell by 3.2% in the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 1,749 shares in the last quarter. Hedge funds and other institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.